Kura Oncology EBIT

Kura Oncology (KURA) currently reports a EBIT of $-310M as of June 2026. That compares with $-200M in the prior-year period — down 55.2% year over year. That is below the Healthcare sector average of $23B. Use the charts on this page to explore Kura Oncology's EBIT history and peer comparisons.

Kura Oncology's EBIT decreased from $-200M to $-310M — a 55.2% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Kura Oncology's EBIT of $-310M is lower than the Healthcare sector average of $23B. That is roughly 101.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Kura Oncology reported $-310M in EBIT as of June 2026. That compares with $-200M in the prior-year period — down 55.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-310M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $23B. From there, open related valuation or income-statement pages for Kura Oncology, and consider following KURA for alerts when major investors trade the stock.